finance
Vitamin Patch Maker Barrière Strikes Walmart Deal, Projects Doubling Revenue by 2026
Vitamin patch company Barrière told CNBC exclusively it is on track to double revenue this year to $10 million. The projection follows a major retail expansion with Walmart and the launch of the first supplement patch for lactose intolerance. A 6:20 video segment details the company's push into the supplement market.
May 6, 7:00 AM·1m read1 source
CnbcAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Vitamin patch brand Barrière is on track to double its revenue in 2026, projecting $10 million total revenue that year, the company told CNBC exclusively. The projection comes as Barrière landed a 1,700 store deal with Walmart. The retailer agreement forms a central piece of the company's expansion into mainstream retail channels.
Barrière is also rolling out the first ever supplement patch for lactose intolerance. The new product aims to address a common dietary need through transdermal delivery rather than traditional pills or gummies. Cnbc reported that Barrière told the network exclusively about its 2026 revenue projection, Walmart deal and lactose intolerance patch launch.
The disclosures arrived alongside a video segment produced by the outlet. The CNBC video segment on Barrière vitamin patches runs 06:20 in length. It examines how the company is attempting to disrupt the supplement industry while outlining potential challenges in scaling a patch-based delivery system.
Barrière's revenue target for 2026 represents a doubling from its current run rate. Company officials positioned the Walmart partnership and new product introduction as key drivers behind the accelerated growth. The 1,700-store Walmart deal marks a significant increase in Barrière's physical retail footprint.
Patches will now reach consumers across a broad network of locations previously unavailable to the brand. The lactose intolerance patch represents an industry first according to Barrière. Its introduction expands the company's portfolio beyond general vitamins into targeted digestive support.
